Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks rallied Tuesday as investors digested some upbeat earnings reports, including better-than-expected results from Apple, which is the largest component of both the Nasdaq Composite and the S&P 500.
Tekmira's (NASDAQ:TKMR) (TSE:TKM) shares have been rising this week ever since the first US case of Ebola emerged in Texas, and are up another 8 percent today after announcing a $1.5 million milestone payment from agricultural giant Monsanto (NYSE:MON).
OrganiGram (CVE:OGI) is currently one of 13 licensed producers for medical marijuana so far in Canada under the government’s new regulations, but the company is the only provider east of Ontario and one of two producers (the sole publicly listed one) growing an organic product.
Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) extended gains on Tuesday after the company said it has taken another step to help combat the Ebola crisis by collaborating with an international consortium to provide an RNAi-based investigational drug for expedited clinical studies in West Africa.
Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) were jumping Monday afternoon after the FDA authorized the company to provide its TKM-Ebola treatment to people with confirmed or suspected Ebola infections.
Alibaba Group Holding (NYSE:BABA) soared in its market debut today, trading as much as 46 percent above its initial public offering price of $68 and making the Chinese e-commerce company one of the most valuable companies in the U.S. The stock opened at $92.70 and nearly hit $100 on the New York Stock Exchange.
Investors interested in Neuralstem recently viewed
- Eco Animal Health Group Plc (AIM: EAH) ECO Animal Health - applying science carefully to animal health markets
- Cellmid (ASX: CDY) Cellmid is the world leader in Midkine Intellectual Property
- Oxford Pharmascience (AIM: OXP) Developing proprietary delivery systems for medicines & supplements
- ReNeuron (AIM: RENE) Leading stem cell company targeting areas of significant unmet medical need
- Supreme Pharmaceuticals (CSE: SL) Targeting opportunities in the medical marijuana and obesity sectors